PMC7292102_01
HE stain of liver metastatic lesion.
IJU5-2-43-g001.jpg
PMC7292102_01_IJU5-2-43-g001.jpg
iju512035-fig-0001
A fine-needle biopsy of the liver lesion showed metastatic pRCC (Memorial Sloan-Kettering Cancer Center risk: intermediate [anemia] and the International Metastatic Renal Cell Carcinoma Database Consortium risk: intermediate [anemia]) (Fig. 1). The detailed protocol for immunostaining and its scoring are described in our previous study.2 Both primary and metastatic tumors in the present case showed higher levels of the Raf expression compared with the other renal tumors included in the tissue microarray (Fig. 3, Table 1).
CT of metastatic lesion (arrow) before (a), 1 month after (b), and 3 months after (c) sorafenib treatment.
IJU5-2-43-g002.jpg
PMC7292102_01_IJU5-2-43-g002.jpg
iju512035-fig-0002
Three months after the introduction of sorafenib, his liver metastasis had reduced in size by about 51%, and he showed no recurrence 5 months after starting sorafenib treatment (Fig. 2).
Immunohistochemistry of Raf expression in primary (a) and liver metastatic (b) lesions.
IJU5-2-43-g003.jpg
PMC7292102_01_IJU5-2-43-g003.jpg
iju512035-fig-0003
The detailed protocol for immunostaining and its scoring are described in our previous study.2 Both primary and metastatic tumors in the present case showed higher levels of the Raf expression compared with the other renal tumors included in the tissue microarray (Fig. 3, Table 1).